Firefly Neuroscience Seeks Massive Share Authorization Hike, Equity Plan Boost

TL;DR

**AIFF is gearing up for massive dilution with a 50x authorized share increase and a continually expanding equity plan – tread carefully.**

AI Summary

Firefly Neuroscience, Inc. (AIFF) is holding its Annual Meeting on October 27, 2025, to address several critical proposals impacting its corporate governance and equity structure. Key proposals include the election of two Class II director nominees to serve until the 2028 Annual Meeting and the ratification of Marcum Canada LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025. Significantly, the company seeks approval to amend its 2024 Long-Term Incentive Plan, increasing the share limit by 317,820 shares of common stock and implementing an automatic annual increase of up to 4% of outstanding shares until January 1, 2035. Furthermore, AIFF proposes a substantial increase in its total authorized shares from 101,000,000 to 5,001,000,000, comprising common stock and a fixed 1,000,000 shares of preferred stock, granting the Board discretion over the timing and amount of this increase. The Board unanimously recommends a 'FOR' vote on all five proposals, including a proposal to adjourn the meeting if necessary to solicit additional proxies.

Why It Matters

This DEF 14A filing reveals Firefly Neuroscience's aggressive strategy to expand its equity capacity, which could significantly dilute existing shareholders if the 5,001,000,000 authorized shares are fully utilized. The proposed increase in the Long-Term Incentive Plan by 317,820 shares, plus an annual 4% automatic increase, signals a strong focus on employee retention and future compensation, potentially at the expense of shareholder value. For investors, this signals a potential for future capital raises or M&A activity, while employees could see enhanced equity incentives. Competitively, this move could provide AIFF with substantial flexibility for strategic maneuvers in the neuroscience sector, but also raises questions about the immediate need for such a vast authorization.

Risk Assessment

Risk Level: high — The proposal to increase authorized shares from 101,000,000 to 5,001,000,000 represents a nearly 50-fold increase, creating significant potential for future dilution. Additionally, the 2024 Long-Term Incentive Plan amendment includes an initial increase of 317,820 shares and an automatic annual increase of up to 4% of outstanding shares until January 1, 2035, which will further dilute existing shareholders over time.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed increase in authorized shares and the expanded equity incentive plan. Consider voting 'AGAINST' Proposal 4 and Proposal 3 if you are concerned about shareholder value erosion, and demand more transparency on the specific uses for such a large share authorization.

Key Numbers

• 5,001,000,000 — Maximum aggregate authorized shares (Proposed increase from 101,000,000 shares)
• 101,000,000 — Current total authorized shares (Baseline before proposed increase)
• 317,820 — Additional shares for Long-Term Incentive Plan (Initial increase to the Plan Share Limit)
• 4% — Annual automatic increase for Long-Term Incentive Plan (Percentage of outstanding shares for automatic annual increase until 2035)
• 1,000,000 — Authorized shares of Preferred Stock (Fixed amount within the new aggregate authorized shares)
• 13,448,848 — Shares of Common Stock outstanding (As of the Record Date, September 4, 2025)
• 2025-10-27T10:00:00.000Z — Annual Meeting Date and Time (Virtual meeting at www.virtualshareholdermeeting.com/AIFF2025)
• 2025-09-04T00:00:00.000Z — Record Date (For stockholders entitled to vote at the Annual Meeting)

Key Players & Entities

• FIREFLY NEUROSCIENCE, INC. (company) — Registrant
• Marcum Canada LLP (company) — Independent registered public accounting firm
• Arun Menawat (person) — Chairman of the Board
• Paul Krzywicki (person) — Corporate Secretary
• Securities and Exchange Commission (regulator) — Oversight body for filings
• Broadridge Corporate Issuer Solutions, Inc. (company) — Stock transfer agent
• $0.0001 (dollar_amount) — Par value per share of Common Stock and Preferred Stock

FAQ

Industry Context

Firefly Neuroscience operates in the biotechnology and medical technology sector, focusing on neurological disorders. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial capital raises to fund their operations and clinical trials, making equity structure and incentive plans critical for attracting and retaining talent.

Regulatory Implications

As a biotechnology company, Firefly Neuroscience is subject to stringent regulations from bodies like the FDA. While this DEF 14A primarily concerns corporate governance, any future product development or commercialization will require adherence to complex regulatory pathways. The proposed increase in authorized shares could facilitate future capital raises, which are often scrutinized by investors regarding dilution.

What Investors Should Do

1. Review the proposed amendments to the 2024 Long-Term Incentive Plan.
2. Evaluate the rationale behind the substantial increase in authorized shares from 101,000,000 to 5,001,000,000.
3. Consider the implications of ratifying Marcum Canada LLP as the independent auditor.
4. Vote on the election of Class II director nominees.

Key Dates

• 2025-10-27: Annual Meeting of Stockholders — Stockholders will vote on critical proposals including director elections, auditor ratification, and amendments to incentive plans and authorized share capital.
• 2025-09-04: Record Date — Establishes the list of stockholders entitled to vote at the Annual Meeting.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of shareholders, including proxy materials. (This document is the primary source of information for the analysis of Firefly Neuroscience, Inc.'s upcoming annual meeting and the proposals being voted on.)

Proxy Statement

A document provided to shareholders before a shareholder meeting, containing information about the matters to be voted on and recommendations from the board of directors. (This document outlines the proposals, director nominees, and auditor appointment that shareholders will vote on at the Annual Meeting.)

Class II Director Nominees

Nominees for a specific class of directors whose terms expire at a particular annual meeting, typically serving a multi-year term. (Shareholders are being asked to elect two Class II director nominees to serve until the 2028 Annual Meeting.)

2024 Long-Term Incentive Plan

A company plan designed to incentivize employees and directors through equity-based awards, such as stock options or restricted stock units. (The company is seeking approval to amend this plan, increasing the share pool and adding an automatic annual increase mechanism.)

Amended and Restated Certificate of Incorporation

The foundational legal document of a corporation that outlines its basic structure, purpose, and powers, which can be amended over time. (A significant proposal involves amending this document to increase the total authorized shares of common stock.)

Year-Over-Year Comparison

This analysis is based on a DEF 14A filing, which typically focuses on upcoming shareholder meetings and proposals rather than year-over-year financial performance comparisons. Information regarding revenue, net income, margins, or debt levels from a previous filing is not present in this document. The key changes highlighted are structural, relating to corporate governance and equity authorization, rather than operational or financial performance metrics.

Key Financial Figures

• $0.0001 — 7,820 shares of common stock, par value $0.0001 per share (the "Common Stock"), and (ii

Filing Documents

• ny20055083x2_def14a.htm (DEF 14A) — 777KB
• logo_fireflyneuro.jpg (GRAPHIC) — 27KB
• logo_fireflyneurox1.jpg (GRAPHIC) — 31KB
• ny20055083x2_pc01.jpg (GRAPHIC) — 874KB
• ny20055083x2_pc02.jpg (GRAPHIC) — 428KB
• ny20055083x2_pvpchart01.jpg (GRAPHIC) — 125KB
• ny20055083x2_pvpchart02.jpg (GRAPHIC) — 120KB
• 0001140361-25-037164.txt ( ) — 5513KB
• aiff-20251027_pre.xml (EX-101.PRE) — 2KB
• aiff-20251027.xsd (EX-101.SCH) — 3KB
• aiff-20251027_lab.xml (EX-101.LAB) — 1KB
• ny20055083x2_def14a_htm.xml (XML) — 102KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED MATTERS 8 MANAGEMENT AND CORPORATE GOVERNANCE 9 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 16 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 18 PROPOSAL 1 ELECTION OF DIRECTORS 39 PROPOSAL 2 RATIFICATION OF THE APPOINTMENT OF MARCUM CANADA LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY'S FISCAL YEAR ENDING DECEMBER 31, 2025 40 REPORT OF AUDIT COMMITTEE 43 PROPOSAL 3 TO APPROVE AMENDMENT NO. 1 TO FIREFLY NEUROSCIENCE, INC. 2024 LONG-TERM INCENTIVE PLAN 44 PROPOSAL 4 TO APPROVE THE BOARD'S DISCRETION TO IMPLEMENT ONE OR MORE AMENDMENTS TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FIREFLY NEUROSCIENCE, INC. 50 PROPOSAL NO. 5 ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE ONE OR MORE PROPOSALS PRESENTED AT THE ANNUAL MEETING 53 OTHER MATTERS 54 ANNEX A A-1 ANNEX B B-1 i TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING Why is the Company Soliciting My Proxy? The Board of Directors is soliciting your proxy to vote at the 2025 Annual Meeting of Stockholders to be held at 10 a.m., Eastern Time, on Monday, October 27, 2025, in virtual format at www.virtualshareholdermeeting.com/AIFF2025, and any postponement or adjournments of the meeting (the "Annual Meeting"). This proxy statement (this "Proxy Statement") along with the accompanying Notice of Annual Meeting of Stockholders summarizes the purposes of the meeting and the information you need to know to vote at the Annual Meeting. Who Can Vote? Only stockholders who owned our common stock, par value $0.0001 per share ("Common Stock") as of the close of business on September 4, 2025 (the "Record Date"), are entitled to vote at the Annual Meeting. On the Record Date, there were 13,448,848 shares of our C

View Full Filing

View this DEF 14A filing on SEC EDGAR